Steve Harris, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address400 Parnassus Avenue, #A551
San Francisco CA 94117
Phone415-682-0914
PronounsHe/Him/His
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. The role of osteoanabolic agents in the management of patients with osteoporosis. Postgrad Med. 2022 Aug; 134(6):541-551. McClung MR, Rothman MS, Lewiecki EM, Hanley DA, Harris ST, Miller PD, Kendler DL. PMID: 35635798.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    2. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. Endocr Pract. 2020 May; 26(Suppl 1):1-46. Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa SJ, Watts NB. PMID: 32427503.
      View in: PubMed   Mentions: 294     Fields:    Translation:Humans
    3. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE EXECUTIVE SUMMARY. Endocr Pract. 2020 May; 26(5):564-570. Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa SJ, Watts NB. PMID: 32427525.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    4. History of etidronate. Bone. 2020 05; 134:115222. Watts NB, Chesnut CH, Genant HK, Harris ST, Jackson RD, Licata AA, Miller PD, Mysiw WJ, Richmond B, Valent D. PMID: 31911206.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    5. Western Osteoporosis Alliance Clinical Practice Series: Treat-to-Target for Osteoporosis. Am J Med. 2019 11; 132(11):e771-e777. Lewiecki EM, Kendler DL, Davison KS, Hanley DA, Harris ST, McClung MR, Miller PD. PMID: 31152714.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    6. Proceedings of the 2017 Santa Fe Bone Symposium: Insights and Emerging Concepts in the Management of Osteoporosis. J Clin Densitom. 2018 Jan - Mar; 21(1):3-21. Lewiecki EM, Bilezikian JP, Carey JJ, Dell RM, Gordon CM, Harris ST, McClung MR, Miller PD, Rosenblatt M. PMID: 29229501.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    7. Diagnosis and Treatment of Osteoporosis Before and After Fracture: A Side-by-Side Analysis of Commercially Insured and Medicare Advantage Osteoporosis Patients. J Manag Care Spec Pharm. 2017 Jul; 23(7):735-744. Weaver J, Sajjan S, Lewiecki EM, Harris ST. PMID: 28650253; PMCID: PMC10398230.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    8. Prevalence and Cost of Subsequent Fractures Among U.S. Patients with an Incident Fracture. J Manag Care Spec Pharm. 2017 Apr; 23(4):461-471. Weaver J, Sajjan S, Lewiecki EM, Harris ST, Marvos P. PMID: 28345441; PMCID: PMC10398116.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    9. Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies. Am J Med. 2017 07; 130(7):862.e1-862.e7. Hanley DA, McClung MR, Davison KS, Dian L, Harris ST, Miller PD, Lewiecki EM, Kendler DL, Writing Group for the Western Osteoporosis Alliance. PMID: 28359721.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    10. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016. Endocr Pract. 2016 Sep 02; 22(Suppl 4):1-42. Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB. PMID: 27662240.
      View in: PubMed   Mentions: 158     Fields:    Translation:Humans
    11. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY. Endocr Pract. 2016 Sep; 22(9):1111-8. Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V, Wimalawansa SJ, Watts NB. PMID: 27643923.
      View in: PubMed   Mentions: 71     Fields:    Translation:Humans
    12. Relationship Between Gastrointestinal Events and Compliance With Osteoporosis Therapy: An Administrative Claims Analysis of the US Managed Care Population. Clin Ther. 2016 May; 38(5):1074-80. Modi A, Sajjan S, Michael Lewiecki E, Harris ST, Papadopoulos Weaver J. PMID: 27112533.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    13. Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis. J Clin Densitom. 2014 Oct-Dec; 17(4):490-5. Lewiecki EM, Miller PD, Harris ST, Bauer DC, Davison KS, Dian L, Hanley DA, McClung MR, Yuen CK, Kendler DL. PMID: 24206867.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    14. Hypoparathyroidism. J Clin Endocrinol Metab. 2013 Jun; 98(6):39A-40A. Bollerslev J, Harris ST, Leder BZ. PMID: 23729019.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Medicines and bone loss. J Clin Endocrinol Metab. 2013 Apr; 98(4):33A-4A. Bollerslev J, Harris ST, Leder BZ. PMID: 23564951.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    16. Before the breaking point: reducing the risk of osteoporotic fracture. J Am Osteopath Assoc. 2013 Feb; 113(2 Suppl 1):S5-24; quiz S25. Forstein DA, Bernardini C, Cole RE, Harris ST, Singer A. PMID: 23425935.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    17. Bone mineral density in patients with alopecia areata treated with long-term intralesional corticosteroids. J Drugs Dermatol. 2013 Feb; 12(2):e36-40. Samrao A, Fu JM, Harris ST, Price VH. PMID: 23377403.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    18. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013 Jan; 126(1):13-20. McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM. PMID: 23177553.
      View in: PubMed   Mentions: 167     Fields:    Translation:Humans
    19. Glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab. 2012 Feb; 97(2):35A. Bollerslev J, Harris ST, Leder BZ. PMID: 22312098.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    20. Bisphosphonates for osteoporosis: benefits and risks. J Clin Endocrinol Metab. 2011 Sep; 96(9):27A, 28A. Bollerslev J, Harris ST, Leder BZ. PMID: 21896893.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. Endocr Pract. 2010 Nov-Dec; 16(6):1016-9. Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM. PMID: 21216723; PMCID: PMC4890158.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    22. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract. 2010 Nov-Dec; 16 Suppl 3:1-37. Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM, AACE Osteoporosis Task Force. PMID: 21224201; PMCID: PMC4876714.
      View in: PubMed   Mentions: 135     Fields:    Translation:Humans
    23. Assessing fracture risk and effects of osteoporosis drugs: bone mineral density and beyond. Am J Med. 2009 Nov; 122(11):992-7. Davison KS, Kendler DL, Ammann P, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, McClung MR, Olszynski WP, Yuen CK. PMID: 19854322.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    24. Current and emerging therapies for osteoporosis. J Fam Pract. 2009 Jul; 58(7 Suppl Osteoporosis):S45-9. Mitchner NA, Harris ST. PMID: 19825319.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    25. Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate. Ann Pharmacother. 2009 Apr; 43(4):577-85. Blumentals WA, Harris ST, Cole RE, Huang L, Silverman SL. PMID: 19318598.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    26. Preventing nonvertebral osteoporotic fractures with extended-interval bisphosphonates: regimen selection and clinical application. Medscape J Med. 2009; 11(1):12. Cole RE, Harris ST. PMID: 19295933; PMCID: PMC2654682.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    27. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study. Bone. 2009 May; 44(5):758-65. Harris ST, Reginster JY, Harley C, Blumentals WA, Poston SA, Barr CE, Silverman SL. PMID: 19168160.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    28. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin. 2008 Jan; 24(1):237-45. Harris ST, Blumentals WA, Miller PD. PMID: 18047776.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    29. Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonates. Ann N Y Acad Sci. 2007 Nov; 1117:273-82. Zaidi M, Epstein S, Harris ST, Kohles JD, Chesnut CH. PMID: 18056047.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    30. Bisphosphonates and osteonecrosis of the jaw. Ann Intern Med. 2006 Nov 21; 145(10):791-2; author reply 792. Watts NB, Harris ST, McClung MR, Bilezikian JP, Greenspan SL, Luckey MM. PMID: 17116933.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    31. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006 Aug; 81(8):1013-22. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S. PMID: 16901023.
      View in: PubMed   Mentions: 266     Fields:    Translation:Humans
    32. Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age. J Rheumatol. 2005 Oct; 32(10):1968-74. Ettinger MP, Felsenberg D, Harris ST, Wasnich R, Skag A, Hiltbrunner V, Wilson K, Schimmer RC, Miller PD. PMID: 16206354.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    33. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res. 2005 Sep; 20(9):1514-24. Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR, Continuing Outcomes Relevant to Evista (CORE) Investigators. PMID: 16059623.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    34. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005 Aug; 26(5):688-703. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK. PMID: 15769903.
      View in: PubMed   Mentions: 218     Fields:    Translation:Humans
    35. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin. 2005 Mar; 21(3):391-401. Chesnut CH, Ettinger MP, Miller PD, Baylink DJ, Emkey R, Harris ST, Wasnich RD, Watts NB, Schimmer RC, Recker RR. PMID: 15811208.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    36. Classification algorithms for hip fracture prediction based on recursive partitioning methods. Med Decis Making. 2004 Jul-Aug; 24(4):386-98. Jin H, Lu Y, Harris ST, Black DM, Stone K, Hochberg MC, Genant HK. PMID: 15271277.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    37. Clinical use of teriparatide in the real world: initial insights. Endocr Pract. 2004 Mar-Apr; 10(2):139-48. Miller PD, Bilezikian JP, Deal C, Harris ST, Ci RP. PMID: 15256332.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansPHPublic Health
    38. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002 Aug; 87(8):3609-17. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R, Mulitple Outcomes of Raloxifene Evaluation Investigators. PMID: 12161484.
      View in: PubMed   Mentions: 122     Fields:    Translation:HumansCTClinical Trials
    Steve's Networks
    Concepts (143)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (5)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-5-g94c7c43e on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.